After beating estimates last quarter by $0.05, Invacare
What analysts say
- Buy, sell, or hold?: Analysts think investors should stand pat on Invacare with two of three analysts rating it hold. Analysts don't like Invacare as much as competitor Symmetry Medical overall. Three out of five analysts rate Symmetry Medical a buy compared to one of three for Invacare.
- Revenue forecasts: On average, analysts predict $436.6 million in revenue this quarter. That would represent a rise of 1.3% from the year-ago quarter.
- Wall Street earnings expectations: The average analyst estimate is earnings of $0.45 per share. Estimates range from $0.43 to $0.47.
What our community says
The majority of CAPS All-Stars see IVC as a good bet, with 65% awarding it an outperform rating. The majority of the Fools are in agreement with the All-Stars as 76.4% give it an outperform rating. Fools are gung-ho about Invacare, though the message boards have been quiet lately with only 34 posts in the past 30 days. Despite the majority sentiment in favor of Invacare, the stock has a middling CAPS rating of three out of five stars.
Revenue has now gone up for three straight quarters.
We can help you keep tabs on your companies with My Watchlist, our free, personalized service. Add Invacare now.
Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.